Thursday, November 5, 2026

Back to the front page

From X

@ACapitalLP 2 clicks

A Capital on X

𝙀𝙭-𝘼𝙣𝙩𝙚 𝙫𝙨. 𝙀𝙭-𝙋𝙤𝙨𝙩 𝘾𝙖𝙩𝙖𝙡𝙮𝙨𝙩𝙨 One of the more important distinctions in catalyst-driven investing is “ex-ante” vs. “ex-post” catalysts (my words). Both can offer significant valuation dislocations, but the mechanics of realizing that value are fundamentally different… “Ex-ante” trades are cleaner. You identify a gap between price and intrinsic value, with an upcoming event (spin-off, asset sale, regulatory decision, etc.) that can force the market to reassess the security. You have a mechanism for value realization and at least (some) visibility into timing. “Ex-post” trades are much harder. Something unexpected happens, investors “shoot first, ask questions later,” and the stock collapses. Deep-value and distressed investors love these situations because the apparent discount to intrinsic value can be enormous. But the event that created the dislocation does absolutely nothing to resolve it. Look at $BAYN, where an identifiable June litigation catalyst helped drive a meaningful rerating. Contrast that with $CODI following its Lugano accounting scandal, where the stock collapsed from the high teens into the single digits. It took months of financial reporting progress, improved visibility, and renewed confidence for the stock to recover even partially. On the flip side, look at $VRRM following its major contract loss, where what initially looked like a massive overreaction was followed by further deterioration, with the stock now at $2.80. The irony is that ex-post trades almost always require a new “mini ex-ante” catalyst to unlock value. Otherwise you’re simply betting that the market eventually recognizes something is cheap. That can take years, and even then the security may never recover anywhere close to its prior valuation. The lesson is that a catalyst creating a valuation gap is not the same as a catalyst closing it. Cheapness is not a catalyst, and the magnitude of a selloff tells you very little about the probability of recovery…

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

VSH Earnings Review

Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…

Thursday Tailwinds #13: Nov 5, 2026

Florida marinas are 92% full as boat counts rise and permits constrain new supply, creating pricing power for existing operators such as…

eToro: Expanding Beyond Crypto

EToro trades at 2.89x EV/FCF with $304 million in trailing free cash flow, expanding from crypto into equities, commodities, currencies and…

CHWY · long

Chewy INC

Chewy (CHWY) is presented as a long opportunity after a prior 2022 short thesis played out.

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

Coupang: 3Q26 Business Recap

Coupang’s product-commerce growth rose 9% as data-leak effects fade, while management expects margins to return to pre-incident levels by…

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.